Inventiva Names Malkomes as CFO Ahead of Lanifibranor Phase 3 Readout

Dow Jones04-23

By Elias Schisgall

Inventiva appointed Axel-Sven Malkomes as its new chief financial officer ahead of the company's planned readout of Phase 3 trial results for lanifibranor, a liver-disease treatment.

Current Chief Financial Officer Jean Volatier will stay on as the biopharmaceutical company's executive vice president, finance & corporate social responsibility.

Malkomes most recently served as CFO of CureVac. He has also served as CFO of Cardio, helping lead its acquisition by Novo Nordisk, as well as CFO and chief business officer at Midigene.

The company also named Susan Coles as its chief legal officer and Pamela Herbster as its chief people officer.

Coles was previously head of legal and finance for Vivet Therapeutics. She also served two stints as Inventiva's general counsel, from 2012 to 2014 and from 2019 to 2021.

Herbster previously led human resources and business operations at Sage Therapeutics.

They are joining Inventiva in advance of its readout of trial results for lanifibranor, a treatment for metabolic dysfunction-associated steatohepatitis. That readout is expected in the fourth quarter of 2026, the company said.

Nathalie Harroy, who currently serves as head of human resources, will also stay with the company.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

April 22, 2026 18:51 ET (22:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629079968?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-23 06:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629079968","market":"other","top_or_hot":-1,"title":"Inventiva Names Malkomes as CFO Ahead of Lanifibranor Phase 3 Readout","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Inventiva appointed Axel-Sven Malkomes as its new chief financial officer ahead of the company's planned readout of Phase 3 trial results for lanifibranor, a liver-disease treatment. \n</p>\n<p>\n  Current Chief Financial Officer Jean Volatier will stay on as the biopharmaceutical company's executive vice president, finance &amp; corporate social responsibility. \n</p>\n<p>\n  Malkomes most recently served as CFO of CureVac. He has also served as CFO of Cardio, helping lead its acquisition by <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>, as well as CFO and chief business officer at Midigene. \n</p>\n<p>\n  The company also named Susan Coles as its chief legal officer and Pamela Herbster as its chief people officer. \n</p>\n<p>\n  Coles was previously head of legal and finance for Vivet <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. She also served two stints as Inventiva's general counsel, from 2012 to 2014 and from 2019 to 2021. \n</p>\n<p>\n  Herbster previously led human resources and business operations at <a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a>. \n</p>\n<p>\n  They are joining Inventiva in advance of its readout of trial results for lanifibranor, a treatment for metabolic dysfunction-associated steatohepatitis. That readout is expected in the fourth quarter of 2026, the company said. \n</p>\n<p>\n  Nathalie Harroy, who currently serves as head of human resources, will also stay with the company. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 22, 2026 18:51 ET (22:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inventiva Names Malkomes as CFO Ahead of Lanifibranor Phase 3 Readout</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInventiva Names Malkomes as CFO Ahead of Lanifibranor Phase 3 Readout\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-23 06:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Inventiva appointed Axel-Sven Malkomes as its new chief financial officer ahead of the company's planned readout of Phase 3 trial results for lanifibranor, a liver-disease treatment. \n</p>\n<p>\n  Current Chief Financial Officer Jean Volatier will stay on as the biopharmaceutical company's executive vice president, finance &amp; corporate social responsibility. \n</p>\n<p>\n  Malkomes most recently served as CFO of CureVac. He has also served as CFO of Cardio, helping lead its acquisition by <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>, as well as CFO and chief business officer at Midigene. \n</p>\n<p>\n  The company also named Susan Coles as its chief legal officer and Pamela Herbster as its chief people officer. \n</p>\n<p>\n  Coles was previously head of legal and finance for Vivet <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. She also served two stints as Inventiva's general counsel, from 2012 to 2014 and from 2019 to 2021. \n</p>\n<p>\n  Herbster previously led human resources and business operations at <a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a>. \n</p>\n<p>\n  They are joining Inventiva in advance of its readout of trial results for lanifibranor, a treatment for metabolic dysfunction-associated steatohepatitis. That readout is expected in the fourth quarter of 2026, the company said. \n</p>\n<p>\n  Nathalie Harroy, who currently serves as head of human resources, will also stay with the company. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 22, 2026 18:51 ET (22:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2629079968","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629079968","pubTimestamp":1776898260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Inventiva appointed Axel-Sven Malkomes as its new chief financial officer ahead of the company's planned readout of Phase 3 trial results for lanifibranor, a liver-disease treatment.Current Chief Financial Officer Jean Volatier will stay on as the biopharmaceutical company's executive vice president, finance & corporate social responsibility.Malkomes most recently served as CFO of CureVac. He has also served as CFO of Cardio, helping lead its acquisition by Novo Nordisk, as well as CFO and chief business officer at Midigene.The company also named Susan Coles as its chief legal officer and Pamela Herbster as its chief people officer.Coles was previously head of legal and finance for Vivet Therapeutics. She also served two stints as Inventiva's general counsel, from 2012 to 2014 and from 2019 to 2021.Herbster previously led human resources and business operations at Sage Therapeutics.They are joining Inventiva in advance of its readout of trial results for lanifibranor, a treatment for m","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IVA":"Inventiva S.A."},"translate_title":"Inventiva在Lanifibranor第三阶段公布之前任命Malkomes为首席财务官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IVA":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Inventiva appointed Axel-Sven Malkomes as its new chief financial officer ahead of the company's planned readout of Phase 3 trial results for lanifibranor, a liver-disease treatment. \n\n\n  Current Chief Financial Officer Jean Volatier will stay on as the biopharmaceutical company's executive vice president, finance & corporate social responsibility. \n\n\n  Malkomes most recently served as CFO of CureVac. He has also served as CFO of Cardio, helping lead its acquisition by Novo Nordisk, as well as CFO and chief business officer at Midigene. \n\n\n  The company also named Susan Coles as its chief legal officer and Pamela Herbster as its chief people officer. \n\n\n  Coles was previously head of legal and finance for Vivet Therapeutics. She also served two stints as Inventiva's general counsel, from 2012 to 2014 and from 2019 to 2021. \n\n\n  Herbster previously led human resources and business operations at Sage Therapeutics. \n\n\n  They are joining Inventiva in advance of its readout of trial results for lanifibranor, a treatment for metabolic dysfunction-associated steatohepatitis. That readout is expected in the fourth quarter of 2026, the company said. \n\n\n  Nathalie Harroy, who currently serves as head of human resources, will also stay with the company. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 22, 2026 18:51 ET (22:51 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive,dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629079968","isCrawlerRequest":true}